GNS, a US-based company that said it deals with the application of Causal AI and simulation technology to discover and validate novel drug targets, simulate clinical trials, and help pharmaceutical and biotech companies discover and develop new medicines faster, announced on Thursday that it has named John Maraganore, PhD as its new strategic advisor.

Dr Maraganore served as the founding CEO and a director of Alnylam. He has held the position of an officer and a member of the management team for Millennium Pharmaceuticals, Inc. He has held the position of director of Molecular Biology and director of Market and Business Development at Biogen, Inc., and a scientist at ZymoGenetics, Inc. and the Upjohn Company.

Presently he is venture partner at ARCH Venture Partners, a venture advisor at Atlas Ventures, and an executive partner at RTW Investments. He is also serving as the chair of the board of directors of Hemab Therapeutics and a member of the board of directors of Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, and the Biotechnology Industry Organization, where he was chair. He is also serving on the board of the Termeer Foundation, as chair of the n-Lorem Foundation Advisory Council, on the Advisory Board of Ariadne Labs, and as a strategic advisor to a number of innovative companies.

Colin Hill, GNS CEO and co-founder, said, 'John is a visionary and an inspiration for the biopharma industry and his perspective and deep insights in life sciences R&D will be incredibly valuable for GNS. On behalf of the rest of our board and all our employees and partners, I'm delighted to welcome John to our team, and I look forward to working closely with him as we continue to grow the leading company in the field of virtual patients and digital twins to support the faster discovery and development of new medicines.'